

Attorney Docket No.: 4990.210-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Blinkovsky *et al.*

Application No.: To Be Assigned

Group Art Unit: To Be Assigned

Filed: November 13, 2000

Examiner: To Be Assigned

For: Carboxypeptidases And Nucleic Acids Encoding Same



INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in PTO form 1449 which is in accordance with the requirements of M.P.E.P. 609. Copies of references were filed with USSN **08/943,714** filed **October 3, 1997**, the benefit of which is claimed under 35 USC 120.


The references are as follows:

1. WO 96/09397
2. Choi *et al.*, Journal of Fermentation and Bioengineering, Vol. 72, No. 3, pp. 214-216. (1991)
3. Azarenkova *et al.*, Biochemistry, Vol. 41, No. 1/1, 99. 15-21. (1976)
4. Svensen *et al.*, FEBS Letters, Vol. 333, No. 1/2, pp. 39-43. (1993)
5. Database WPI, XP 002054568, JP 54 037 894 A (Tanabe Seiyaku)
6. Database WPI, XP 002054569, JP 48 035 459 B (Kikkoman Shoyu KK)

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of the application or date of entry into the national stage of an international application or **before** the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. § 1.97(b). Therefore, no fee is due.

Respectfully submitted,



Date: November 13, 2000

Robert L. Starnes, Reg. No.: 41,324
Novo Nordisk Biotech, Inc.
1445 Drew Avenue
Davis, CA 95616
(530) 757-8100

FORM PTO-1449
(Rev. 2-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEAtty. Docket No. **4990.210-US**Serial No. **To Be Assigned**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant **Blinkovsky et al.**Filing Date **November 13, 2000**Group **To Be Assigned**JC555 U.S. PTO
09/712338

11/13/00

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		WO 96/09397	03/28/96	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Choi et al., Journal of Fermentation and Bioengineering, Vol. 72, No. 3, pp. 214-216 (1991)
		Azarenkova et al., Biochemistry, Vol. 41, No. 1/1, pp. 15-21 (1976)
		Svensen et al., FEBS Letters, Vol. 333, No. 1/2, pp. 39-43 (1993)
		Database WPI, XP 002054568, JP 54 037 894 (Tanabe Seivaku)
		Database WPI, XP 002054569, JP 48 035 459 (Kikkoman Shovu KK)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.